Human Growth Hormone
Product
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Market
Partner
NGENLA™
Growth Hormone Deficiency (Pediatric)
COMMERCIAL
NGENLA™
Growth Hormone Deficiency (Adults)
GLOBAL REGISTRATIONAL STRATEGIES UNDERWAY
NGENLA™
Other Pediatric Indications
PHASE 3
Immuno-Oncology
Product
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Market
Partner
Therapeutics LASER*
Treatment of Solid Tumors
IND ENABLING | PHASE 1 EXPECTED IN H1 2024
Therapeutics LASER*
Treatment of Leukemia/Lymphoma
IND ENABLING
Therapeutics Stealth LASER*
Treatment of Solid Tumors
IND ENABLING
Multispecific Immune Modulation
Hematologic Malignancies and Solid Tumors; CAR T Cells
Discovery-stage
*Lymphocyte Activator and Survival Extension Receptor (LASER) Antibodies
Antiviral
Product
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Market
Partner
HIV Trispecific Antibody
Treatment and Prevention of HIV
PHASE 1
EBV Nanoparticle Vaccine
Prevention of EBV-related diseases
IND ENABLING
COVID Multispecific Antibody
Treatment and Prevention of COVID-19
IND ENABLING
